The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Brain Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Brain Neoplasms


Psychiatry related information on Brain Neoplasms


High impact information on Brain Neoplasms

  • Reduced levels of N-acetylaspartate in malignant brain tumors [11].
  • In brat or prospero mutants, both daughter cells grow and behave like neuroblasts leading to the formation of larval brain tumors [12].
  • These findings provide evidence that alterations in the NF2 transcript occur not only in the hereditary brain neoplasms typically associated with NF2, but also as somatic mutations in their sporadic counterparts and in seemingly unrelated tumour types [13].
  • Children under 36 months of age with biopsy-proved malignant brain tumors were treated postoperatively with two 28-day cycles of cyclophosphamide plus vincristine, followed by one 28-day cycle of cisplatin plus etoposide [14].
  • It has been hypothesized that a high dietary intake of nitrosamines and their precursors, nitrites and nitrates, is a risk factor for brain tumors [15].

Chemical compound and disease context of Brain Neoplasms


Biological context of Brain Neoplasms


Anatomical context of Brain Neoplasms


Gene context of Brain Neoplasms

  • In addition, we found that the transcriptional repressor protein, lethal (3) malignant brain tumor protein, L(3)MBT, and the histone deacetylase, Rpd3, associated with the Myb-MuvB complex [29].
  • We report here that in 55% (64/117) of cases, histologically normal brain tissue adjacent to primary human brain tumors lacked detectable MGMT activity [methyl excision repair-defective (Mer-) status] [30].
  • A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors [31].
  • Ptc+/- p53-/- mice provide a useful model for investigation of the molecular bases of medulloblastoma and for evaluation of the efficacy of therapeutic intervention strategies in a spontaneously arising endogenous brain tumor [32].
  • Notch1 and notch2 have opposite effects on embryonal brain tumor growth [33].
  • Our results suggest that common variants in the SOD2, SOD3, and CAT genes may influence brain tumor risk [34].
  • 61% of the malignant brain tumors expressed programmed death ligand-1 (PD-L1), while the inhibitory PD-1 receptor was expressed on CD4+ effector cells present in 26% of tumors [35].

Analytical, diagnostic and therapeutic context of Brain Neoplasms


  1. Glutamate release promotes growth of malignant gliomas. Takano, T., Lin, J.H., Arcuino, G., Gao, Q., Yang, J., Nedergaard, M. Nat. Med. (2001) [Pubmed]
  2. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Bell, D.W., Varley, J.M., Szydlo, T.E., Kang, D.H., Wahrer, D.C., Shannon, K.E., Lubratovich, M., Verselis, S.J., Isselbacher, K.J., Fraumeni, J.F., Birch, J.M., Li, F.P., Garber, J.E., Haber, D.A. Science (1999) [Pubmed]
  3. Mutations of the hSNF5/INI1 gene in renal rhabdoid tumors with second primary brain tumors. Savla, J., Chen, T.T., Schneider, N.R., Timmons, C.F., Delattre, O., Tomlinson, G.E. J. Natl. Cancer Inst. (2000) [Pubmed]
  4. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Breedveld, P., Beijnen, J.H., Schellens, J.H. Trends Pharmacol. Sci. (2006) [Pubmed]
  5. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Barba, D., Hardin, J., Sadelain, M., Gage, F.H. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  6. Molecular diversity of astrocytes with implications for neurological disorders. Bachoo, R.M., Kim, R.S., Ligon, K.L., Maher, E.A., Brennan, C., Billings, N., Chan, S., Li, C., Rowitch, D.H., Wong, W.H., DePinho, R.A. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  7. Images of the brain: past as prologue. Wagner, H.N. J. Nucl. Med. (1986) [Pubmed]
  8. Macrophage-colony stimulating factor (M-CSF) in the cerebrospinal fluid. Gallo, P., Pagni, S., Giometto, B., Piccinno, M.G., Bozza, F., Argentiero, V., Tavolato, B. J. Neuroimmunol. (1990) [Pubmed]
  9. Brain tumor presenting as anorexia nervosa in a 19-year-old man. Lin, L., Liao, S.C., Lee, Y.J., Tseng, M.C., Lee, M.B. J. Formos. Med. Assoc. (2003) [Pubmed]
  10. Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants. Bennett, M.R., Rizvi, T.A., Karyala, S., McKinnon, R.D., Ratner, N. J. Neurosci. (2003) [Pubmed]
  11. Reduced levels of N-acetylaspartate in malignant brain tumors. McConnell, J.R. CA: a cancer journal for clinicians. (1999) [Pubmed]
  12. Asymmetric segregation of the tumor suppressor brat regulates self-renewal in Drosophila neural stem cells. Betschinger, J., Mechtler, K., Knoblich, J.A. Cell (2006) [Pubmed]
  13. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Bianchi, A.B., Hara, T., Ramesh, V., Gao, J., Klein-Szanto, A.J., Morin, F., Menon, A.G., Trofatter, J.A., Gusella, J.F., Seizinger, B.R. Nat. Genet. (1994) [Pubmed]
  14. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. Duffner, P.K., Horowitz, M.E., Krischer, J.P., Friedman, H.S., Burger, P.C., Cohen, M.E., Sanford, R.A., Mulhern, R.K., James, H.E., Freeman, C.R. N. Engl. J. Med. (1993) [Pubmed]
  15. Relation between maternal diet and subsequent primitive neuroectodermal brain tumors in young children. Bunin, G.R., Kuijten, R.R., Buckley, J.D., Rorke, L.B., Meadows, A.T. N. Engl. J. Med. (1993) [Pubmed]
  16. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. O'Driscoll, B.R., Hasleton, P.S., Taylor, P.M., Poulter, L.W., Gattameneni, H.R., Woodcock, A.A. N. Engl. J. Med. (1990) [Pubmed]
  17. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Trojan, J., Johnson, T.R., Rudin, S.D., Ilan, J., Tykocinski, M.L., Ilan, J. Science (1993) [Pubmed]
  18. alpha-Difluoromethylornithine-induced polyamine depletion of 9L tumor cells modifies drug-induced DNA cross-link formation. Tofilon, P.J., Deen, D.F., Marton, L.J. Science (1983) [Pubmed]
  19. Influence of gastrin on human astrocytic tumor cell proliferation. Camby, I., Salmon, I., Danguy, A., Pasteels, J.L., Brotchi, J., Martinez, J., Kiss, R. J. Natl. Cancer Inst. (1996) [Pubmed]
  20. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. Glantz, M.J., Choy, H., Kearns, C.M., Mills, P.C., Wahlberg, L.U., Zuhowski, E.G., Calabresi, P., Egorin, M.J. J. Natl. Cancer Inst. (1995) [Pubmed]
  21. Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. Chen, J., Willingham, T., Shuford, M., Nisen, P.D. J. Clin. Invest. (1996) [Pubmed]
  22. Association between brain tumors and menopausal status. Schlehofer, B., Blettner, M., Wahrendorf, J. J. Natl. Cancer Inst. (1992) [Pubmed]
  23. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Vajkoczy, P., Knyazev, P., Kunkel, A., Capelle, H.H., Behrndt, S., von Tengg-Kobligk, H., Kiessling, F., Eichelsbacher, U., Essig, M., Read, T.A., Erber, R., Ullrich, A. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  24. Effect of cell-cell interactions on drug sensitivity and growth of drug-sensitive and -resistant tumor cells in spheroids. Tofilon, P.J., Buckley, N., Deen, D.F. Science (1984) [Pubmed]
  25. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Frebourg, T., Kassel, J., Lam, K.T., Gryka, M.A., Barbier, N., Andersen, T.I., Børresen, A.L., Friend, S.H. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  26. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Lu, Q.R., Park, J.K., Noll, E., Chan, J.A., Alberta, J., Yuk, D., Alzamora, M.G., Louis, D.N., Stiles, C.D., Rowitch, D.H., Black, P.M. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  27. Reduced level of DNA cross-links and sister chromatid exchanges in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant rat brain tumor cells. Bodell, W.J., Rupniak, H.T., Rasmussen, J., Morgan, W.F., Rosenblum, M.L. Cancer Res. (1984) [Pubmed]
  28. The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Warnke, P.C., Blasberg, R.G., Groothuis, D.R. Ann. Neurol. (1987) [Pubmed]
  29. Identification of a Drosophila Myb-E2F2/RBF transcriptional repressor complex. Lewis, P.W., Beall, E.L., Fleischer, T.C., Georlette, D., Link, A.J., Botchan, M.R. Genes Dev. (2004) [Pubmed]
  30. Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Silber, J.R., Blank, A., Bobola, M.S., Mueller, B.A., Kolstoe, D.D., Ojemann, G.A., Berger, M.S. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  31. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Rubin, J.B., Kung, A.L., Klein, R.S., Chan, J.A., Sun, Y., Schmidt, K., Kieran, M.W., Luster, A.D., Segal, R.A. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  32. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Wetmore, C., Eberhart, D.E., Curran, T. Cancer Res. (2001) [Pubmed]
  33. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Fan, X., Mikolaenko, I., Elhassan, I., Ni, X., Wang, Y., Ball, D., Brat, D.J., Perry, A., Eberhart, C.G. Cancer Res. (2004) [Pubmed]
  34. Oxidative response gene polymorphisms and risk of adult brain tumors. Rajaraman, P., Hutchinson, A., Rothman, N., Black, P.M., Fine, H.A., Loeffler, J.S., Selker, R.G., Shapiro, W.R., Linet, M.S., Inskip, P.D. Neuro-oncology (2008) [Pubmed]
  35. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Jacobs, J.F., Idema, A.J., Bol, K.F., Nierkens, S., Grauer, O.M., Wesseling, P., Grotenhuis, J.A., Hoogerbrugge, P.M., de Vries, I.J., Adema, G.J. Neuro-oncology (2009) [Pubmed]
  36. Aspartame consumption in relation to childhood brain tumor risk: results from a case-control study. Gurney, J.G., Pogoda, J.M., Holly, E.A., Hecht, S.S., Preston-Martin, S. J. Natl. Cancer Inst. (1997) [Pubmed]
  37. Differential expression of mRNAs for JC virus large and small tumor antigens in brain tissues from progressive multifocal leukoencephalopathy patients with and without AIDS. Ishaq, M., Stoner, G.L. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  38. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. Schold, S.C., Herndon, J.E., Burger, P.C., Halperin, E.C., Vick, N.A., Cairncross, J.G., Macdonald, D.R., Dropcho, E.J., Morawetz, R., Bigner, D.D. J. Clin. Oncol. (1993) [Pubmed]
  39. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Janus, T.J., Kim, E.E., Tilbury, R., Bruner, J.M., Yung, W.K. Ann. Neurol. (1993) [Pubmed]
  40. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Saleh, M., Stacker, S.A., Wilks, A.F. Cancer Res. (1996) [Pubmed]
WikiGenes - Universities